The global clinical oncology next-generation sequencing market is poised for exponential growth, according to a recent market analysis. Estimated at a value of US$ 449.4 million in 2022, this sector is projected to soar to a staggering US$ 1.14 billion by 2029, marking a remarkable Compound Annual Growth Rate (CAGR) of 16.3%.
The proliferation of next-generation sequencing (NGS) in clinical oncology has been a game-changer, enabling advanced personalized treatment strategies for cancer patients worldwide. This surge in adoption reflects the industry’s commitment to innovative diagnostic and therapeutic approaches, driven by the escalating global burden of cancer.
Get a PDF Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-9543
“Next-generation sequencing has emerged as a cornerstone in the fight against cancer,” remarked FMI. “Its ability to decipher genomic information with unprecedented accuracy has opened new avenues for tailored treatment plans, offering hope to patients and clinicians alike.”
At present, the clinical oncology next-generation sequencing market accounts for approximately 3.8% of the global NGS market. Kits and reagents, constituting 59.8% of the market in 2022, are leading the charge, with widespread adoption across diverse applications.
As the global healthcare landscape continues to evolve, fueled by technological advancements and a growing demand for precision medicine, the clinical oncology next-generation sequencing market is poised to redefine cancer treatment paradigms. With a relentless focus on innovation and collaboration, stakeholders are poised to revolutionize cancer care and usher in a new era of hope and healing.
Key Takeaways: Clinical Oncology Next-Generation Sequencing Market (2022-2029)
- Market Size and Growth: The market is expected to reach US$ 1.14 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 16.3% from 2022 to 2029. This growth is attributed to the increasing adoption of next-generation sequencing (NGS) for personalized cancer treatment.
- Drivers: Rising focus on personalized medicine, growing awareness of NGS benefits in oncology, and increasing investment in cancer research are key drivers of the market.
- Segments: The market is segmented by technology, workflow, application, and end-use. Kits & reagents are expected to witness significant growth within the market.
- Regional Analysis: North America is expected to hold a dominant position due to well-developed healthcare infrastructure and technological advancements. However, Asia-Pacific is anticipated to show the fastest growth rate.
- Future Outlook: The market is expected to witness continued growth due to factors like increasing government support for genomics research, rising disposable income, and growing geriatric population.
For More Report Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-9543
Key Companies Profiled:
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd
- Oxford Nanopore Technologies
- Agilent Technologies
- Thermo Fisher Scientific Inc, PerkinElmer, Inc.
- Becton, Dickinson and Company
- QIAGEN N.V.
- Pacific Biosciences of California, Inc.
- BGI Group
- Takara Bio, Inc
- Creative-Biolabs
- Mogene LC
Clinical oncology next-generation sequencing Market by Category:
By Component:
- Sequencing Platforms
- Sequencing Products
- Kits and Reagents
- Services
By Technology:
- Ion Semiconductor Sequencing
- Pyro-Sequencing
- Synthesis Sequencing (SBS)
- Real Time Sequencing (SMRT)
- Ligation Sequencing
- Reversible Dye Termination Sequencing
- Nano-Pore Sequencing
By Application:
- Whole Tumor Genome Sequencing
- Whole Tumor Exome Sequencing
- Targeted Tumor Genome Profiling
- Tumor Transcriptome Sequencing
- Tumor-normal Comparisons
- Others
By End User:
- Hospital Laboratories
- Clinical Research Organizations
- Diagnostic Laboratories
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/9543
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube